Aksoy Fuat, Gökçe Erhan, Balkan Eyüp Anıl, Dündar Halit Ziya, Kaya Ekrem
Department of General Surgery, Bursa Uludağ University Faculty of Medicine, Bursa, Türkiye.
Turk J Surg. 2024 Dec 27;40(4):267-274. doi: 10.47717/turkjsurg.2024.6474. eCollection 2024 Dec.
It is known that surgical treatment is advantageous in terms of efficacy and survival in colorectal cancer and neuroendocrine tumor liver metastases. Our aim in this study was to determine the results of surgical treatment of non-colorectal (NCR), non-neuroendocrine tumor (NNET) liver metastases (LM).
A total of 125 patients having NCR and NNET were included in the study. Demographic characteristics of the patients, histological features of the tumor, time from resection of the primary tumor to the first diagnosis of liver metastases, synchronous and metachronous presentations of hepatic metastases with primary malignancy, type of resection, postoperative complications, length of hospital stay, and survival were analyzed retrosepctively.
Median follow-up time was 21 (1-132) months. Mean overall survival (OS) and mean proression free survival (PFS) were 29.86 ± 2.4 and 21.23 ± 2.1 months respectively. Most of the cases were LM of breast (n= 33, 26.4%), gastric (n= 25, 20.0%) and gastrointestinal stromal tumors (GIST) (n= 16, 12.8%). Interval from resection of primary tumor to the diagnosis of LM was 20.90 ± 28.9 (0-144) months. OS and DFS rates were found respectively as; 78% and 69% at one year, 45% and 38% at three years, 32% and 21% at five years and 3.2% and 1.6% at 10 years. Breast cancer liver metastases had the longest OS and PFS. Pancreatic cancer and gastric cancer group significantly have shorter OS than the other groups.
According to our data, the results are better in breast and GIST liver metastases, and the place of surgical treatment in pancreatic and malignant melanoma liver metastases is controversial.
已知手术治疗在结直肠癌和神经内分泌肿瘤肝转移的疗效和生存率方面具有优势。本研究的目的是确定非结直肠癌（NCR）、非神经内分泌肿瘤（NNET）肝转移（LM）的手术治疗结果。
本研究共纳入125例患有NCR和NNET的患者。回顾性分析患者的人口统计学特征、肿瘤的组织学特征、从原发肿瘤切除到首次诊断肝转移的时间、肝转移与原发性恶性肿瘤的同时性和异时性表现、切除类型、术后并发症、住院时间和生存率。
中位随访时间为21（1 - 132）个月。平均总生存期（OS）和平均无进展生存期（PFS）分别为29.86±2.4个月和21.23±2.1个月。大多数病例为乳腺癌肝转移（n = 33，26.4%）、胃癌肝转移（n = 25，20.0%）和胃肠道间质瘤（GIST）肝转移（n = 16，12.8%）。从原发肿瘤切除到诊断肝转移的间隔时间为20.90±28.9（0 - 144）个月。OS和DFS率分别为：1年时78%和69%，3年时45%和38%，5年时32%和21%，10年时3.2%和1.6%。乳腺癌肝转移的OS和PFS最长。胰腺癌和胃癌组的OS明显短于其他组。
根据我们的数据，乳腺癌和GIST肝转移的结果较好，而手术治疗在胰腺癌和恶性黑色素瘤肝转移中的地位存在争议。
